In silico approaches which are used in pharmacy
Authors:
Open Access
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
- Vol. 14, (4) , 225-239
Abstract
This mini-review theoretically illustrates the in silico methods used in the pharmacy field to enhance drug discovery and development and reduce preclinical studies. It is shown that in silico methods are computational-based approaches that study the structure, properties, and activities of molecules using computer simulations and mathematical algorithms. These results highlight the importance of obtaining data that can affect the prediction of in vivo results. Artificial intelligence and machine learning development enhance in silico methods such as quantitative structure-activity relationship, molecular placement, and physiological-based pharmacokinetics, which are usually used. This approach not only saves time and costs but also offers ease of application. Studies conducted to evaluate the use of in silico methods in areas such as pharmacology, toxicology, and pharmaceuticals are provided as examples. It was concluded that over time, in silico methods usage and development increased due to their ability to predict the in vivo performance of the drug.Keywords
This publication has 86 references indexed in Scilit:
- Computer-Aided Drug Design2021
- Computer-Aided Drug Design Methods2016
- QSAR Methods2016
- In silico methods for drug repurposing and pharmacologyWIREs Mechanisms of Disease, 2016
- Analysis of Proteomic Data for Toxicological Applications2015
- In silico subtractive genomics for target identification in human bacterial pathogensDrug Development Research, 2010
- Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis2009
- History of Research on Nicotinic and Muscarinic Cholinergic Receptors2007
- Evaluation of the TOPKAT system for predicting the carcinogenicity of chemicalsEnvironmental and Molecular Mutagenesis, 2001
- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate1998